[{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"90e2c2df-d5c6-4f93-8b0d-0ff266e30b82","acronym":"","url":"https://clinicaltrials.gov/study/NCT01306045","created_at":"2021-01-18T05:18:49.422Z","updated_at":"2024-07-02T16:35:10.788Z","phase":"Phase 2","brief_title":"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","source_id_and_acronym":"NCT01306045","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • sunitinib • lapatinib • Koselugo (selumetinib) • MK-2206"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 647","initiation":"Initiation: 02/08/2011","start_date":" 02/08/2011","primary_txt":" Primary completion: 02/12/2014","primary_completion_date":" 02/12/2014","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-09"},{"id":"55442488-1d80-4dbc-ae5e-2273f0f75787","acronym":"","url":"https://clinicaltrials.gov/study/NCT01802320","created_at":"2021-01-18T07:58:45.783Z","updated_at":"2024-07-02T16:36:55.387Z","phase":"Phase 2","brief_title":"Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01802320","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • PIK3CA • PTEN","pipe":" | ","alterations":" BRAF mutation • PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA expression","tags":["KRAS • BRAF • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MK-2206"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 08/05/2015","study_completion_date":" 08/05/2015","last_update_posted":"2019-09-20"},{"id":"f984c669-5c9b-447e-b95e-48bf7957acd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01277757","created_at":"2021-01-18T05:10:57.904Z","updated_at":"2024-07-02T16:37:04.571Z","phase":"Phase 2","brief_title":"Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT01277757","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PIK3CA • PTEN","pipe":" | ","alterations":" ER positive • PIK3CA mutation • EGFR positive • PIK3CA mutation + PTEN mutation","tags":["ER • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • EGFR positive • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MK-2206"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2018-12-19"},{"id":"43f17c8a-0e4f-4cf8-b237-118639894987","acronym":"","url":"https://clinicaltrials.gov/study/NCT01253447","created_at":"2023-08-14T10:10:52.407Z","updated_at":"2024-07-02T16:37:07.496Z","phase":"Phase 2","brief_title":"AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT01253447","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MK-2206"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2018-08-27"},{"id":"1132504b-149e-4bfb-bb55-2a76a95ae6af","acronym":"","url":"https://clinicaltrials.gov/study/NCT01021748","created_at":"2021-01-17T17:50:17.221Z","updated_at":"2025-02-25T15:04:39.894Z","phase":"Phase 1","brief_title":"A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)","source_id_and_acronym":"NCT01021748","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • MK-2206"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 11/23/2009","start_date":" 11/23/2009","primary_txt":" Primary completion: 11/26/2012","primary_completion_date":" 11/26/2012","study_txt":" Completion: 07/16/2014","study_completion_date":" 07/16/2014","last_update_posted":"2018-08-07"},{"id":"516633a7-2c69-4fa1-9ae2-12725023586a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01344031","created_at":"2021-01-18T05:29:11.380Z","updated_at":"2024-07-02T16:37:08.754Z","phase":"Phase 1","brief_title":"MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer","source_id_and_acronym":"NCT01344031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • MK-2206 • anastrozole"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 04/21/2011","start_date":" 04/21/2011","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":"","study_completion_date":"","last_update_posted":"2018-07-23"},{"id":"702a7bee-1abe-4383-a05e-f3c42e8ae277","acronym":"","url":"https://clinicaltrials.gov/study/NCT01369849","created_at":"2021-01-18T05:36:41.184Z","updated_at":"2024-07-02T16:37:17.871Z","phase":"Phase 1/2","brief_title":"Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT01369849","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CCND1 • IGH • CD38 • CD5 • ITGA4 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CCND1 • IGH • CD38 • CD5 • ITGA4 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • MK-2206 • bendamustine • Novex (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2017-09-15"},{"id":"2795dd80-ae53-4f2e-99f2-aa09eed84d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT01312753","created_at":"2021-04-05T17:17:49.523Z","updated_at":"2025-02-25T16:23:34.844Z","phase":"Phase 2","brief_title":"PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer","source_id_and_acronym":"NCT01312753","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MK-2206"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2017-09-05"},{"id":"b31d8b74-74fb-4cfc-bc6e-3594ba487e7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01263145","created_at":"2021-01-18T05:05:52.987Z","updated_at":"2024-07-02T16:37:18.429Z","phase":"Phase 1","brief_title":"MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer","source_id_and_acronym":"NCT01263145","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MKI67","pipe":"","alterations":" ","tags":["MKI67"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • MK-2206"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/05/2011","start_date":" 01/05/2011","primary_txt":" Primary completion: 10/19/2012","primary_completion_date":" 10/19/2012","study_txt":" Completion: 10/19/2012","study_completion_date":" 10/19/2012","last_update_posted":"2017-08-25"},{"id":"a98a82e7-611b-4f17-9bb7-d253109fa467","acronym":"","url":"https://clinicaltrials.gov/study/NCT01283035","created_at":"2021-01-18T05:12:18.241Z","updated_at":"2024-07-02T16:37:31.057Z","phase":"Phase 2","brief_title":"A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer","source_id_and_acronym":"NCT01283035","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MK-2206"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2016-06-24"}]